The Kirby Institute, UNSW Sydney, Sydney, Australia.
Merck Canada Inc., Montreal, Canada.
Int J Drug Policy. 2019 Jan;63:29-38. doi: 10.1016/j.drugpo.2018.10.012. Epub 2018 Nov 23.
This study evaluated competency related to HCV testing, management and treatment among physicians practicing in clinics offering opioid agonist treatment (OAT).
C-SCOPE is a study consisting of a self-administered survey among physicians practicing at clinics providing OAT in Australia, Canada, Europe and USA between April-May 2017. A 7-point scale was used to measure < average competence (score >4 of 7) related to HCV testing, management and treatment.
Among 203 physicians (40% USA, 45% Europe, 14% Australia/Canada) 21% were addiction medicine specialists, 29% psychiatrists, and 70% were metro/urban [mean PWID managed, 51; years of experience, 11]. The majority perceived HCV testing (82%) and treatment (85%) among PWID as important. The minority reported < average competence with respect to regular screening (12%) and interpretation of HCV test results (14%), while greater proportions reported < average competence in advising patients about new HCV therapies (28%), knowledge of new treatments (37%), and treatment/management of HCV (40%). In adjusted analysis, factors independently associated with < average self-reported competency related to the ability to treat HCV and manage side effects included fewer years in medical practice, fewer numbers of patients treated for HCV infection in the past six months, not having obtained information on screening, diagnosing or treatment of HCV, not having attended any training on HCV in the past year, and not having read or consulted AASLD/IDSA, EASL or other guidelines for HCV.
Physicians treating HCV infection among PWID attending OAT clinics recognized the importance of HCV testing and treatment. However, self-perceived competency related to HCV management and treatment was low, highlighting the importance of improved HCV education and training among physicians practicing in clinics offering OAT.
本研究评估了在提供阿片类药物激动剂治疗(OAT)的诊所工作的医生在 HCV 检测、管理和治疗方面的能力。
C-SCOPE 是一项研究,包括 2017 年 4 月至 5 月期间在澳大利亚、加拿大、欧洲和美国提供 OAT 的诊所工作的医生进行的自我管理调查。使用 7 分制来衡量 HCV 检测、管理和治疗方面的能力<平均水平(得分> 7 分中的 4 分)。
在 203 名医生中(40%来自美国,45%来自欧洲,14%来自澳大利亚/加拿大),21%是成瘾医学专家,29%是精神科医生,70%是城市/市区医生[管理的平均 IDU,51;经验年限,11]。大多数医生认为 IDU 中的 HCV 检测(82%)和治疗(85%)很重要。少数医生报告说,在 HCV 检测结果的定期筛查(12%)和解释(14%)方面能力<平均水平,而更多的医生报告说在向患者提供有关新 HCV 治疗方法的建议(28%)、新治疗方法的知识(37%)以及 HCV 的治疗/管理(40%)方面能力<平均水平。在调整分析中,与治疗 HCV 和管理副作用的能力相关的自我报告能力<平均水平的独立相关因素包括行医年限较短、过去六个月治疗 HCV 感染的患者人数较少、未获得 HCV 筛查、诊断或治疗方面的信息、过去一年未参加任何 HCV 培训以及未阅读或咨询 AASLD/IDSA、EASL 或其他 HCV 指南。
在 OAT 诊所治疗 HCV 感染的 IDU 的医生认识到 HCV 检测和治疗的重要性。然而,他们对 HCV 管理和治疗的自我感知能力较低,这突出了提高在提供 OAT 的诊所工作的医生 HCV 教育和培训的重要性。